Autologous Anti-LGR5 CAR-T Cells CNA3103

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous T-lymphocytes transduced to express a chimeric antigen receptor (CAR) targeting the cancer stem cell (CSC) marker leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-LGR5 CAR-T cells CNA3103 selectively target, binds to and lyse LGR5-expressing tumor cells. LGR5, a member of the Wnt signaling pathway, is overexpressed on certain cancer cells; it plays a key role in CSC proliferation and survival, tumor initiation, growth, and metastasis. Its expression is linked to poor survival and poor patient response to therapy. CNA3103 contains the antigen-biding domain of the humanized monoclonal LGR5 antibody BNC101.

**Synonyms:** - CAN 3103 - CAN-3103 - CAN3103 - LGR5-targeted Autologous CAR-T Cells CNA3103 - Leucine-rich Repeat-containing G Protein-coupled Receptor 5-targeted Autologous CAR T-cells CNA3103